7OC0 Stock Overview A precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. More details
Rewards Risk Analysis + 3 more risks
See All Risk Checks Capture your thoughts, links and company narrative
OncoCyte Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for OncoCyte Historical stock prices Current Share Price US$0.18 52 Week High US$15.50 52 Week Low US$2.76 Beta 1.53 1 Month Change 0% 3 Month Change -94.29% 1 Year Change -98.84% 3 Year Change -99.35% 5 Year Change -99.37% Change since IPO -99.89%
Recent News & Updates
Oncocyte Corp. Announces Additional Favorable Data Regarding Its Lead Assay Vitagraft™? Dec 03
OncoCyte Corporation to Report Q3, 2024 Results on Nov 12, 2024 Nov 07
Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial Oct 08 OncoCyte Corporation announced that it expects to receive $10.203435 million in funding from Bio-Rad Laboratories, Inc. Oct 03
OncoCyte Corporation has completed a Follow-on Equity Offering in the amount of $0.316184 million. Aug 10
OncoCyte Corporation has filed a Follow-on Equity Offering in the amount of $7.5 million. Aug 09
See more updates
Oncocyte Corp. Announces Additional Favorable Data Regarding Its Lead Assay Vitagraft™? Dec 03
OncoCyte Corporation to Report Q3, 2024 Results on Nov 12, 2024 Nov 07
Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial Oct 08 OncoCyte Corporation announced that it expects to receive $10.203435 million in funding from Bio-Rad Laboratories, Inc. Oct 03
OncoCyte Corporation has completed a Follow-on Equity Offering in the amount of $0.316184 million. Aug 10
OncoCyte Corporation has filed a Follow-on Equity Offering in the amount of $7.5 million. Aug 09
OncoCyte Corporation to Report Q2, 2024 Results on Aug 08, 2024 Aug 02
Oncocyte Announces Notice of Prior Non-Compliance and Subsequent Compliance with Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2) Jul 13 OncoCyte Corporation announced that it expects to receive $3.5 million in funding from Bio-Rad Laboratories, Inc. Jun 25
OncoCyte Corporation Appoints Andrea James as Chief Financial Officer Jun 18
Oncocyte Corporation Announces Promising Results in A Phase 2 Clinical Trial Jun 05
Oncocyte Corporation Announces Favorable Oncocyte Vitgraft Kidney Study Results May 31
OncoCyte Corporation to Report Q1, 2024 Results on May 15, 2024 May 15
OncoCyte Corporation, Annual General Meeting, Jun 28, 2024 May 01 OncoCyte Corporation announced that it has received $15.8 million in funding Apr 26
Broadwood Capital, Inc. Engages with OncoCyte Corporation Apr 16 OncoCyte Corporation announced that it expects to receive $15.8 million in funding Apr 12
OncoCyte Corporation announced delayed annual 10-K filing Apr 02
Oncocyte Corporation Begins FDA Submissions Process for VitaGraft Transplant Assays Dec 06
OncoCyte Corporation to Report Q3, 2023 Results on Nov 09, 2023 Nov 04
Oncocyte Corporation Announces Vitagraft Kidney Transplant Diagnostic Test Receives Cms Coverage Aug 29
Oncocyte Corporation Announces Executive Changes Aug 11
OncoCyte Regains Compliance with Nasdaq Listing Requirements Aug 10
OncoCyte Corporation to Report Q2, 2023 Results on Aug 10, 2023 Aug 04
Oncocyte Corporation Announces the Publication of New Data Demonstrating Vitagraft Kidney's Novel Ability to Help Physicians Treat Kidney Transplant Patients Jul 26
Oncocyte Announces 1-For-20 Reverse Stock Split to Regain Compliance with Minimum Bid Price Requirement Jul 25
Jennifer Levin Carter and John Peter Gutfreund Not to Stand for Re-Election to the Board of Directors of OncoCyte Corporation May 21 OncoCyte Corporation, Annual General Meeting, Jun 23, 2023
OncoCyte Receives Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard Feb 14
Oncocyte Applies to Transfer the Listing of its Common Stock from The Nasdaq Global Market to The Nasdaq Capital Market Feb 01
OncoCyte Corporation Announces Reduction of Workforce Dec 17 OncoCyte Corporation Announces Executive Changes
Melinda Griffith Notifies Oncocyte Corporation F Her Resignation from the Board, Effective January 1, 2023 Nov 24
Third quarter 2022 earnings released: US$0.081 loss per share (vs US$0.15 loss in 3Q 2021) Nov 16
High number of new directors Nov 16
Third quarter 2022 earnings released: US$0.079 loss per share (vs US$0.15 loss in 3Q 2021) Nov 12
OncoCyte Corporation to Report Q3, 2022 Results on Nov 10, 2022 Oct 28
Oncocyte Corporation Appoints James Liu as Controller and Principal Accounting Officer Sep 28
Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on Determarx to CMS Sep 08
Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer Aug 25
Independent Chairman recently bought €142k worth of stock Aug 19
OncoCyte Corporation Receives Non-Compliance Letter from Nasdaq Aug 16
Second quarter 2022 earnings released: US$0.073 loss per share (vs US$0.12 loss in 2Q 2021) Aug 12 OncoCyte Corporation Appoints Anish John as Chief Financial Officer
OncoCyte Corporation Announces the Appointment of John Peter Gutfreund as Independent Member of its Board of Directors Aug 02
OncoCyte Corporation to Report Q2, 2022 Results on Aug 10, 2022 Jul 28
OncoCyte Corporation Announces Resignation of Li Yu as Controller and Principal Accounting Officer Jul 02
OncoCyte Corporation(NasdaqGM:OCX) dropped from Russell 2000 Dynamic Index Jun 26
OncoCyte Corporation, Annual General Meeting, Jul 15, 2022 Jun 09
First quarter 2022 earnings released: US$0.11 loss per share (vs US$0.048 loss in 1Q 2021) May 13
Oncocyte Corporation Completes Validation of TheraSure™ Transplant Monitor Test May 06
High number of new directors Apr 27
Broadwood Capital Engages in Discussions with OncoCyte Corporation Apr 16 OncoCyte Corporation has completed a Follow-on Equity Offering in the amount of $35.000001 million. Apr 14
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 12
OncoCyte Corporation to Report Q4, 2021 Results on Mar 10, 2022 Mar 03
OncoCyte Corporation Announces Peer-Reviewed Publication in Cancers Showing Utility of DetermaCNI™ Blood-Only Monitoring Test to Detect Recurrence Following Surgery in Epithelial Ovarian Cancer Jan 05
Oncocyte Corporation Announces Results from DetermaIO™ Test Dec 10
Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.10 loss in 3Q 2020) Nov 10
Broadwood Partners Engages in Discussions with OncoCyte Corporation Sep 25
Oncocyte Corporation Announces Oral Presentation of New Data on Its DetermaIO Immunotherapy Response Test at the European Society for Medical Oncology Annual Meeting Sep 21
Oncocyte Corporation Launches Nationwide, Prospective, Real-World Registry for Patients with Potentially Curable Early-Stage Lung Cancer Aug 18
Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.14 loss in 2Q 2020) Aug 11
Forecast to breakeven in 2024 May 21
First quarter 2021 earnings released: US$0.048 loss per share (vs US$0.13 loss in 1Q 2020) May 21
CEO, President & Director recently bought €44k worth of stock Mar 27
OncoCyte Corporation Announces Peer-Reviewed Publication of Data Assessing Use of DetermaIO™ to Identify Patients Likely to Benefit from Immunotherapy Across Multiple Tumor Types Mar 17
Oncocyte Corporation Announces Formation of Medical Advisory Board Mar 11
Oncocyte Corporation Announces Agreement with MultiPlan Network, Expanding Patient Access to Determarx™ Mar 05
OncoCyte Corporation to Report Q4, 2020 Results on Mar 16, 2021 Mar 04
New 90-day high: €4.70 Feb 09
OncoCyte Corporation has completed a Follow-on Equity Offering in the amount of $35.01 million. Feb 06
OncoCyte Corporation (AMEX:OCX) entered into an agreement to acquire Chronix Biomedical, Inc. for $23.9 million. Feb 04
Oncocyte Corporation to Present New Data At the IASLC 2020 World Conference on Lung Cancer Jan 29
New 90-day high: €3.02 Jan 21
OncoCyte Corporation Enters into an Exclusive Sublicense Agreement in the PRC Territory Dec 18
Burning Rock Announces an Exclusive in-Licensing of a Risk Stratification Test for Early Stage Lung-Cancer Patients from Oncocyte in China Dec 16
New 90-day high: €1.68 Dec 02
Oncocyte Presents New Data on its DetermaIO™ Test at Association for Molecular Pathology (AMP) 2020 Conference Nov 19 Shareholder Returns 7OC0 DE Biotechs DE Market 7D 0% 2.4% -0.4% 1Y -98.8% -10.2% 7.9%
See full shareholder returns
Return vs Market: 7OC0 underperformed the German Market which returned 5.9% over the past year.
Price Volatility Is 7OC0's price volatile compared to industry and market? 7OC0 volatility 7OC0 Average Weekly Movement n/a Biotechs Industry Average Movement 7.3% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.1% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 7OC0's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 7OC0's volatility change over the past year.
About the Company OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies.
Show more OncoCyte Corporation Fundamentals Summary How do OncoCyte's earnings and revenue compare to its market cap? 7OC0 fundamental statistics Market cap €21.48m Earnings (TTM ) -€16.24m Revenue (TTM ) €1.04m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 7OC0 income statement (TTM ) Revenue US$1.10m Cost of Revenue US$1.03m Gross Profit US$75.00k Other Expenses US$17.27m Earnings -US$17.20m
Last Reported Earnings
Jun 30, 2023
Earnings per share (EPS) -2.09 Gross Margin 6.81% Net Profit Margin -1,562.03% Debt/Equity Ratio 0%
How did 7OC0 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/10/22 11:36 End of Day Share Price 2023/07/25 00:00 Earnings 2023/06/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources OncoCyte Corporation is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Mark Massaro BTIG Paul Knight Janney Montgomery Scott LLC null null KeyBanc Capital Markets Inc.
Show 5 more analysts 
